- Home
- TENX vs SCYX Comparison
TENX vs SCYX Comparison
Compare TENX & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TENX
- SCYX
- Stock Information
- Founded
- TENX 1967
- SCYX 1999
- Country
- TENX United States
- SCYX United States
- Employees
- TENX N/A
- SCYX N/A
- Industry
- TENX Biotechnology: Pharmaceutical Preparations
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- TENX Health Care
- SCYX Health Care
- Exchange
- TENX Nasdaq
- SCYX Nasdaq
- Market Cap
- TENX 27.3M
- SCYX 32.3M
- IPO Year
- TENX N/A
- SCYX 2014
- Fundamental
- Price
- TENX $7.34
- SCYX $0.66
- Analyst Decision
- TENX Strong Buy
- SCYX Strong Buy
- Analyst Count
- TENX 3
- SCYX 1
- Target Price
- TENX $16.67
- SCYX $3.00
- AVG Volume (30 Days)
- TENX 96.6K
- SCYX 573.5K
- Earning Date
- TENX 11-14-2025
- SCYX 11-13-2025
- Dividend Yield
- TENX N/A
- SCYX N/A
- EPS Growth
- TENX N/A
- SCYX N/A
- EPS
- TENX N/A
- SCYX N/A
- Revenue
- TENX N/A
- SCYX $3,257,000.00
- Revenue This Year
- TENX N/A
- SCYX $20.23
- Revenue Next Year
- TENX N/A
- SCYX $933.90
- P/E Ratio
- TENX N/A
- SCYX N/A
- Revenue Growth
- TENX N/A
- SCYX N/A
- 52 Week Low
- TENX $4.32
- SCYX $0.65
- 52 Week High
- TENX $8.24
- SCYX $1.49
- Technical
- Relative Strength Index (RSI)
- TENX 54.72
- SCYX 28.92
- Support Level
- TENX $7.00
- SCYX $0.68
- Resistance Level
- TENX $7.72
- SCYX $0.82
- Average True Range (ATR)
- TENX 0.49
- SCYX 0.05
- MACD
- TENX -0.02
- SCYX -0.01
- Stochastic Oscillator
- TENX 75.12
- SCYX 4.07
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.